Lilly's VERVE-102 Shows Significant LDL-C Reduction in Phase 1b Trial
VERVE-102 reduced PCSK9 levels by up to 88% and LDL-C by up to 62% in Phase 1b trial, with effects lasting up to 18 months.
Asset / Drug
Drug and asset intelligence for VERVE-102 with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.